Hong G Biotechnology (Shanghai)
Biosynthesis of Human Milk Oligosaccharides for nutrition.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Series A | |
| Total Funding | 000k | ||
Synaura Biotechnology (Shanghai) Co., Ltd., also known as Hong G Biotechnology, is a biosynthesis company established in Shanghai in February 2022. The firm focuses on the research, development, and industrialization of Human Milk Oligosaccharides (HMOs), which are the third most abundant solid component in human breast milk and contribute to infant gut health, immune system support, and cognitive development. Synaura's core business involves producing high-purity HMO raw materials through microbial fermentation for clients in the infant formula, nutrition, and health food industries. Its product applications also extend to biomedicine and agriculture.
The company has achieved significant regulatory milestones, becoming the first Chinese enterprise to receive Self-Affirmed GRAS (Generally Recognized as Safe) certification in the U.S. in June 2023 and the only domestic HMO supplier approved by China's National Health Commission (NHC) for its 2'-FL (2'-Fucosyllactose) product in October 2023. In August 2024, it also received GRAS certification from the U.S. FDA for the same product. Synaura provides full lifecycle solutions to its customers, from laboratory research to large-scale production and regulatory support.
Synaura has secured significant funding to support its growth. In May 2024, the company completed a pre-Series A financing round of nearly CNY 100 million, led by CICC Capital's Qide Fund and followed by Moutai Fund. Investors also include Shunwei Capital, Abiochem Biotechnology Co., and a subsidiary of China Mengniu Dairy, Beihai Mengniu Venture Capital. This capital is being used for new product R&D, laboratory construction, and commercial expansion.
Keywords: Human Milk Oligosaccharides, HMO, biosynthesis, synthetic biology, infant nutrition, food ingredients, microbial fermentation, nutritional enhancers, infant formula, gut health, cognitive development, immune system, 2'-Fucosyllactose, GRAS certified, CICC Capital, Mengniu, Moutai Fund, Shunwei Capital, food technology, China.